Tepotinib: all 26 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerRecruitingNCT07619339Phase 1
• Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedRecruitingNCT06908993Phase 3
• Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentRecruitingNCT06106802Phase 2
• Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ CarcinomaRecruitingNCT05439993Phase 1/2
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy ParticipantsCompletedNCT05213481Phase 1Results posted
• Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy ParticipantsCompletedNCT05203822Phase 1Results posted
• Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)TerminatedNCT04515394Phase 2Results posted
• Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of TepotinibCompletedNCT04204902Phase 1Results posted
• Effect of Tepotinib on PK of CYP3A Substrate MidazolamCompletedNCT03628339Phase 1Results posted
• Tepotinib Hepatic Impairment TrialCompletedNCT03546608Phase 1Results posted
• Effect of a Proton Pump Inhibitor on the PK of TepotinibCompletedNCT03531762Phase 1Results posted
• Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran EtexilateCompletedNCT03492437Phase 1Results posted
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Phase 2Results posted
• c-Met Second-Line Hepatocellular CarcinomaCompletedNCT02115373Phase 1/2Results posted
• Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Phase 1/2Results posted
• Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)CompletedNCT01982955Phase 1/2Results posted
• A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid TumorsCompletedNCT01832506Phase 1Results posted
• First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid TumorsCompletedNCT01014936Phase 1Results posted
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerActive, not recruitingNCT06083857Phase 1/2
• POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingNCT05782361Phase 1
• A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsWithdrawnNCT05120960Phase 1
• CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCTerminatedNCT04739358Phase 1/2
• Tepotinib in Solid Tumors Harboring MET AlterationsStatus unknownNCT04647838Phase 2
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2

← Tepotinib overview